Ribavirin |
Inhibition of RSV replication |
High toxicity |
|
|
Difficult administration |
|
|
FDA approved |
RSV604 |
Inhibition of RSV replication |
Safety, Tolerability and Pharmacokinetic |
|
|
Study in Healthy Subjects complete |
|
|
Phase I, complete; Phase II, in progress |
17-DMAG |
Inhibition of the heat-shock protein hsp 90 |
Impairs the RSV replication |
|
|
Antitumoral drug |
|
|
No clinical trial |
HR121 and HR212 |
Fusion inhibitor peptides |
IC50 of 4·13 and 0·95 μm, respectively |
|
|
No clinical trial |
JNJ2408068 and BMS-433771 |
Chemical compounds that prevent the fusion process |
Phase I/II, discontinued |
RFI-641 |
Blocks viral F protein-mediated fusion and cell syncytium formation |
Anti-RSV agent with potent in vitro and in vivo activity |
|
|
Phase I/II, discontinued |
ALN-RSV01 |
Small interfering RNA specific against NS1 |
Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected with Respiratory Syncytial Virus complete |